Meeting
2019 ASCO Annual Meeting
Correlation between mutation landscape and clinical outcomes of neoadjuvant therapy in HER2-positive breast cancer patients.
Authors
Ning Liao
Department of Breast Cancer, Cancer Center, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
Ning Liao , Yulei Wang , Kai Li , Bo Chen , Guo-Chun Zhang , XueRui Li , Liping Guo , Li Cao , Chong-Yang Ren , Ling-Zhu Wen , Minghan Jia , Cheukfai Li , Hsiaopei Mok , Xiaoqing Chen , Guangnan Wei , Jiali Lin , Ting Hou , Han Han-Zhang , Zhou Zhang , Jing Liu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Citation
J Clin Oncol 37, 2019 (suppl; abstr 579)
DOI
10.1200/JCO.2019.37.15_suppl.579
Abstract #
579
Poster Bd #
71
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Whole-exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients (pts) treated with prior trastuzumab (T): A correlative analysis of TBCRC003.
First Author: Nikhil Wagle
Poster
2023 ASCO Genitourinary Cancers Symposium
Association of biomarkers and outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) treated with immune checkpoint inhibitors (ICIs).
First Author: Kevin R Reyes
Poster
2022 ASCO Annual Meeting
Circulating tumor DNA (ctDNA) in predicting residual disease after neoadjuvant chemoradiotherapy (nCRT) for esophageal squamous cell carcinoma (ESCC).
First Author: Zhichao Liu
Poster
2019 ASCO Annual Meeting
Distinct mutational landscape between HR+ and HR- HER2+ early-stage breast cancer patients.
First Author: Bo Chen